Any feedback?
Literature summary for 2.4.1.244 extracted from
- Molecular cloning and characterization of a novel human beta1,4-N-acetylgalactosaminyltransferase, beta4GalNAc-T3, responsible for the synthesis of N,N'-diacetyllactosediamine, GalNAc beta1-4GlcNAc (2003), J. Biol. Chem., 278, 47534-47544.
Cloned(Commentary)
| Cloned (Comment) | Organism |
|---|---|
| truncated form of the human enzyme is expressed in HEK293T cells as a soluble protein | Homo sapiens |
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| additional information | Homo sapiens | the enzyme could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans | ? | - |
? |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | Q6L9W6 | - |
- |
Purification (Commentary)
| Purification (Comment) | Organism |
|---|---|
- |
Homo sapiens |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| colon | highly expressed in | Homo sapiens | - |
| stomach | highly expressed in | Homo sapiens | - |
| testis | highly expressed in | Homo sapiens | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| additional information | the enzyme could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans | Homo sapiens | ? | - |
? | |
| additional information | the most efficient acceptor substrate in the N-glycans examined is a non-fucosylated bi-antennary one. The enzyme shows no activity towards chondroitin-related acceptors containing GlcUA as their non-reducing termini | Homo sapiens | ? | - |
? | |
| UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | 45% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + Gal-beta-(1,4)-GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
| UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | 51.7% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | - |
? | |
| UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | 21.6% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
| UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | 5% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
| UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
| UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | 87.1% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
| UDP-GalNAc + GlcNAcbeta-O-benzyl | - |
Homo sapiens | UDP + GalNAc-beta-(1,4)-GlcNAcbeta-O-benzyl | - |
? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| beta1,4-N-acetylgalactosaminyltransferase III | - |
Homo sapiens |
| beta1,4-N-acetylgalactosaminyltransferase IV | - |
Homo sapiens |
| beta1,4-N-acetylgalactosaminyltransferase-III | - |
Homo sapiens |
| beta4GalNAc-T3 | - |
Homo sapiens |
| beta4GalNAc-T4 | - |
Homo sapiens |
| N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 2 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2026.1 (March 2026)
Legal
Curated at
Member of
![DSMZ Digital Diversity]()
![Global Core Biodata Resource]()
![ELIXIR Core Data Resource]()
![German Network for Bioinformatics Infrastructure]()
